Amazon launches six-month $6 prescriptions to Prime members

The new benefit program follows Walmart's announcement and seeks to disrupt the prescription drug market.

| More on:
woman chatting online on her macbook

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Amazon (NASDAQ: AMZN) announced today that it is launching a new prescription program for members of its Prime loyalty program, less than a day after Walmart (NYSE: WMT) said it was offering Walmart+ members a discounted prescription service as well.

Having acquired PillPack in 2018, Amazon has been looking to leverage its ability to buy prescription medicine in bulk and provide savings to members in a bid to take a large slice of the $360 billion prescription drug market.

Like the Walmart program, Amazon's new service is looking for patients who take just a small number of fairly common medicines, such as those used to treat high blood pressure and diabetes; they'll pay as little as $1 per month and receive a six-month supply.

Six months is typically longer than what insurance companies will pay for, so consumers could see real savings by enrolling in the healthcare prescription program. As Prime members, they'd also be entitled to receive free two-day delivery.

The new offer is an expansion of the Amazon Pharmacy benefit announced last month that allows Prime members to comparison shop for savings through its network of 60,000 pharmacies. It noted Prime members save 80% on generic medications and 40% on name-brand ones through Amazon Pharmacy.

Walmart just introduced Walmart+ RX, which also provides significant discounts on commonly used medications. It notes that members of Walmart+, a loyalty program the retailer launched to challenge Amazon Prime, can get some common medications free while saving up to 85% on others.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Rich Duprey has no position in any of the stocks mentioned. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Amazon. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. The Motley Fool Australia has recommended Amazon. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

red arrow representing a rise of the share price with a man wearing a cape holding it at the top
Share Market News

Goldman Sachs reveals 2026 predictions for S&P 500 and other global markets

What's the outlook?

Read more »

A businesman's hands surround a circular graphic with a United States flag and dollar signs, indicating buying and selling US shares
ETFs

Own IVV ETF? Here are your returns for 2025

US stocks outperformed ASX shares but the stronger Aussie dollar eroded returns for IVV ETF investors.

Read more »

A woman pulls her jumper up over her face, hiding.
International Stock News

Here's how the US Magnificent Seven stocks performed in 2025

Not so magnificent: 5 of the 7 stocks underperformed the S&P 500 and Nasdaq Composite.

Read more »

the australian flag lies alongside the united states flag on a flat surface.
Share Market News

US stocks vs. ASX shares in 2025

Which market came out on top?

Read more »

A female engineer inspects a printed circuit board for an artificial intelligence (AI) microchip company.
International Stock News

Should you really invest in AI stocks in 2026? Here's what other investors are saying

Is AI headed for a bubble? Or is there still room for growth?

Read more »

Happy teen friends jumping in front of a wall.
International Stock News

4 reasons to buy Nvidia stock like there's no tomorrow

Nvidia's 2026 is shaping up to be just as good as 2025.

Read more »

Hand with AI in capital letters and AI-related digital icons.
International Stock News

2 AI stocks to buy in January and hold for 20 years

Investing in these tech leaders can help you profit from a generational opportunity.

Read more »

A woman wearing a black and white striped t-shirt looks to the sky with her hand to her chin contemplating buying ASX shares today as the market rebounds
International Stock News

Where will Nvidia stock be in 1 year?

It's starting to head down. Is that a worrisome trend?

Read more »